A phaseII study of irinotecan with bevacizumab as third line treatment for patients with metastatic colorectal cancer after failure to irinotecan who have progressed on bevacizumab with oxaliplatin-based chemotherapy in second line.
Active, not recruitingJPRN-UMIN000009910
Tsuchiura kyodo general hospitalcolorectal cancer
Start: 2013-02-01Target: 25Updated: 2026-06-29